BANK VONTOBEL/CALL/NOVO NORDISK ADR B/105/0.1/20.12.24 | Market Closed - Bid/Ask 18:53:24 16/07/2024 BST | Pre-market 07:12:30 | |||
| 3.64 EUR | -0.82% |
|
3.635 | -0.14% |
| Current month | -8.77% | ||
| 1 month | -8.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 16/07/24 | 3.64 | -0.82% |
| 15/07/24 | 3.67 | -3.17% |
| 12/07/24 | 3.79 | +7.67% |
| 11/07/24 | 3.52 | -7.12% |
| 10/07/24 | 3.79 | +2.71% |
Real-time Boerse Frankfurt Warrants
Last update July 16, 2024 at 06:53 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM7SE2 |
| ISIN | DE000VM7SE29 |
| Date issued | 02/01/2024 |
| Strike | 105 $ |
| Maturity | 20/12/2024 (157 Days) |
| Parity | 10 : 1 |
| Emission price | 1.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.3 € |
|---|---|
| Lowest since issue | 1.26 € |
| Spread | 0.01 € |
| Spread % | 0.27% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
